The first placebo-controlled trial of opioids in acute low back and neck pain.
FDA rejected Outlook Therapeutics’ Lucentis rival, and the company’s stock plunged
The FDA has rejected Outlook Therapeutics’ ophthalmic formulation of bevacizumab for wet AMD, an eye disorder that can cause blurred vision or blind spots. In